Clinical Trial

nCartes Rolls Out REDCap Integration in Collaboration with UC Davis Medical Center

FREMONT, Calif., Oct. 21, 2024 /PRNewswire/ -- nCartes, Inc, a leader in EHR-to-EDC clinical trial data fulfillment, has gone live…

3 months ago

HuidaGene Therapeutics Appoints TJ Cradick, PhD as Chief Technology Officer to Lead Delivery Science and Genome Editing Innovations

SHANGHAI and MIDDLETOWN, Del., Oct. 21, 2024 /PRNewswire/ -- HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company pioneering CRISPR-based programmable genome medicines,…

3 months ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIAMI, FL / ACCESSWIRE / October 21, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a leading pre-clinical-stage pharmaceutical development company, is…

3 months ago

NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence

ZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage…

3 months ago

Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment

GENEVA, SWITZERLAND / ACCESSWIRE / October 21, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a…

3 months ago

Kaia Health Appoints Adam Pellegrini as Global CEO And Launches The First Digital Pulmonary Rehab Program In Partnership With The COPD Foundation

NEW YORK, Oct. 19, 2024 /PRNewswire/ -- Kaia Health (Kaia), a leading digital health company, announces the appointment of Adam…

3 months ago

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia

NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing…

3 months ago

NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS)

SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…

3 months ago